Noida-based startup Redcliffe Lifetech has raised $61 million led by LeapFrog Investments (LeapFrog), with participation from Healthquad, Schroders, LC Nueva, Growth Spark Ventures and existing investors Chiratae Ventures and Alkemi Venture Partners.

The investment will be used to expand Redcliffe’s geographic reach across India, with a focus on expanding its low-cost but high quality Direct to Consumer Diagnostics into tier 2, 3 and 4 cities, providing affordable, rapid, and convenient pathology services from glucose to genetics in millions of households.

Funding will also be used to scale Redcliffe’s platform and increase its product offerings to radiology, disease data profiling and lifestyle management, furthering its mission to shift India’s healthcare focus from treatment to early diagnosis and prevention.  

Redcliffe delivers world-class diagnostics services in its network of 22state-of-the-art labs across 14 cities, several of which are already NABL accredited. Redcliffe also has a team of key-opinion leaders in the pathology sector who oversee operations and quality. 

The startup’s unique omni-channel infrastructure, which combines innovative online channels with a fleet of 400 highly-trained phlebotomists operating in 100+ cities with home sample collection and an off-line network of 500 collection centres, enables the company to offer more than 3,500 different pathology and specialised tests including genetics at highly affordable prices around 25-60% less than traditional competitors.